Source: Eur Respir J, 58 (4) 2003229; 10.1183/13993003.03229-2020
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Linda J.T.M. van der Sande, Quirijn Jöbsis, Michiel A.G.E. Bannier, Ewoudt M.W. van de Garde, Jan J.M. Coremans, Frank de Vries, Edward Dompeling, Johanna H.M. Driessen. The risk of community-acquired pneumonia in children using gastric acid suppressants. Eur Respir J, 58 (4) 2003229; 10.1183/13993003.03229-2020

Member's Comments

No comment yet.

Related content which might interest you: The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Risk factors of community-acquired pneumonia in children Source: Eur Respir J 2010; 36: 1221-1222 Year: 2010 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly Source: Eur Respir J 2013; 41: 923-928 Year: 2013 Inhaled drugs as risk factors for community-acquired pneumonia Source: Eur Respir J 2010; 36: 1080-1087 Year: 2010 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Peculiarities of community-acquired pneumonia in tobacco-smoking patients Source: Annual Congress 2009 - Tobacco: from smoke to disease Year: 2009 Mixed community-acquired pneumonia in hospitalised patients Source: Eur Respir J 2006; 27: 795-800 Year: 2006 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Inhaled drugs as risk factors for community-acquired pneumonia Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Predisposing factors for bacteremia in patients with community-acquired pneumonia and positive pneumococcal urinary antigen Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Risk factors for drug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Impact of aspiration pneumonia in community-acquired pneumonia and healthcare-associated pneumonia Source: Annual Congress 2012 - CT findings: educational posters Year: 2012 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 The etiological agents of community-acquired pneumonia in our hospital Source: Eur Respir J 2006; 28: Suppl. 50, 735s Year: 2006